

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**  
**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Masitinib for the treatment of unresectable or metastatic  
gastrointestinal stromal tumours after treatment with imatinib**

**Batch 28**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees noted that children and young adolescents are often excluded from clinical trials there is an unmet clinical need in this population.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The manufacturer confirmed that the anticipated UK marketing authorisation will be for adults only. This means that the population of children and young adolescents will be outside the scope of the proposed NICE appraisal and consequently this does not represent an equalities issue for the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft scope were required.

4. Have any additional stakeholders related to potential equality issues

Technology Appraisals: Scoping  
Equality impact assessment for the proposed Single Technology Appraisal of masitinib for the treatment of unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib

Issue date: September 2013

been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders relating to potential equalities issues were identified during the scoping process so no changes to the matrix were necessary.

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 03 09 2013